Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001370368-21-000055
Filing Date
2021-07-21
Accepted
2021-07-21 06:55:27
Documents
59
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 6-K nvs-20210630.htm   iXBRL 6-K 14125
2 99.1 FINANCIAL REPORT Q2 2021 nvs-20210630-99_1.htm EX-99 190957
3 99.2 INTERIM FINANCIAL REPORT nvs-20210630-99_2.htm   iXBRL EX-99 4266023
9 IMAGE logo.jpg GRAPHIC 26773
10 IMAGE coverifr.jpg GRAPHIC 120114
  Complete submission text file 0001370368-21-000055.txt   16737677

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nvs-20210630_cal.xml EX-101.CAL 62241
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nvs-20210630_def.xml EX-101.DEF 434786
6 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nvs-20210630_lab.xml EX-101.LAB 1784702
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvs-20210630_pre.xml EX-101.PRE 438043
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvs-20210630.xsd EX-101.SCH 505718
11 EXTRACTED XBRL INSTANCE DOCUMENT nvs-20210630_htm.xml XML 3780886
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Filer) CIK: 0001114448 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-15024 | Film No.: 211102748
SIC: 2834 Pharmaceutical Preparations